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Current guidelines for the acute management of severe 
sepsis in pediatric and adult patients place prime impor-
tance on early, rapid, and substantial infusion of intra-
venous ﬂ  uids [1,2]. Th  e immediate aim is to correct a 
possible ﬂ  uid responsive hypodynamic circulation [1-3]. 
Beyond this, the common assumption is that expansion 
of eﬀ  ective circulating volume will attenuate hypotension, 
ameliorate the perceived impaired peripheral and end-
organ perfusion, and correct abnormalities of base deﬁ  cit 
and lactate. Curiously, this assumption is held despite the 
well-known fact that cardiac output is often elevated in 
septic adults [4-6] and children [7,8] even though 
myocardial performance may be impaired [9]. Further-
more, in children, sepsis-induced myocardial dysfunction 
[10] may increase the chance of ﬂ  uid unresponsiveness. 
In fact, in both adults and children, no controlled data 
exist that increases in cardiac output due to volume 
expansion are beneﬁ  cial or even reliably achieved [11]. 
Moreover, no human data show that substantial 
(>20 mL/kg) ﬂ  uid resuscitation reliably improves blood 
pressure or end-organ perfusion (an elusive outcome 
given that organ blood ﬂ   ow cannot be accurately 
measured in septic humans). Finally, experi  mental data 
show that organ perfusion is supranormal in 
hyperdynamic sepsis [12] and that ﬂ  uid resuscitation may 
increase mortality [13].
Th   e publication of FEAST (Fluid Expansion As 
Supportive Th   erapy in critically ill African children) [14] 
challenges the widely held totemic beliefs in the 
protective power of ﬂ  uids in severe sepsis. It also breaks 
the taboo that has made any challenge to ﬂ  uid therapy in 
the sepsis paradigm an act of unspeakable tribal treason. 
Yet FEAST is the ﬁ  rst large and randomized study of the 
relationship between volume and composition of 
intravenous ﬂ  uids and clinical outcome in acute severe 
sepsis. Th   e results challenge the status quo.
FEAST enrolled Sub-Saharan African children with a 
severe febrile illness (prostration, coma, or respiratory 
distress) and clinical evidence of impaired peripheral 
perfusion. Overall, 3,141 patients without severe hypo-
ten  sion were randomly assigned to one of three groups 
(n = 1,047 in each group): 20 to 40 mL/kg boluses of 5% 
albumin or 0.9% saline or no bolus ﬂ  uids (FEAST A). All 
three groups were given intravenous maintenance ﬂ  uids 
(2.5 to 4 mL/kg per hour), blood transfusion if the 
hemoglobin was less than 5  g/dL (20  mL/kg over the 
course of 4  hours), and appropriate antibiotics, anti-
malarials, anti  convulsants, antipyretics, and blood sugar 
management as indicated. Th  e primary endpoint was 
mortality at 48 hours.
By 8 hours, the median cumulative volumes (including 
transfused blood) received were 40, 40, and 10.1 mL/kg 
for the albumin bolus, saline bolus, and control arms, 
respectively. Most of this diﬀ  erence occurred over the 
course of the ﬁ  rst two hours. Overall 48-hour mortality 
was 9.5% and most deaths occurred within 24 hours, but 
a striking diﬀ   erence was found between the control 
group and the bolus ﬂ  uid groups: 48-hour mortality rates 
were 7.3%, 10.6%, and 10.5% for the control, albumin 
bolus, and 0.9% bolus groups, respectively. Th  e  48-hour 
mortality of the combined bolus group had increased by 
45% (P = 0.003).
Not only are the overall results clinically and statis  ti-
cally signiﬁ  cant but a dose eﬀ  ect is evident. After 2,535 
subjects had been enrolled, the initial sample size was 
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As part of this amendment, the bolus volume was 
increased from 20 to 40 mL/kg. However, enrollment was 
ceased after a further 606 subjects (total of 3,141 subjects) 
because of safety concerns about excess harm to the bolus 
groups. Th   e postamendment mortality of the bolus groups 
(12.1%) was higher than that in pre  amend  ment group 
(10.2%), and there was no change between preamendment 
and postamendment outcomes for the control patients. 
Th   e postamendment eﬀ   ect suggests that mortality 
increased because the dose of bolus ﬂ  uids increased.
What conclusions can intensivists working in modern 
ICUs draw from FEAST? First, the pediatric nature of the 
cohort (median age of 2 years) should invite caution in 
extrapolating these ﬁ   ndings to an adult population. 
Second, 59% of the patients had malaria, although the 
adverse eﬀ   ect of bolus ﬂ   uids was signiﬁ   cant in both 
malarial and nonmalarial subgroups. Th  ird, there was 
insuﬃ   cient information about the causes of death, details 
of which would allow a more insightful analysis of the 
mechanisms linking bolus ﬂ   uid administration to 
mortality. Finally, and very importantly, the FEAST 
‘package’ did not include ICU admission or the use of 
mechanical ventilation, inotropic or vasopressor drugs, 
or continuous renal replacement therapy (CRRT).
Th  ere is no evidence that, when ICU supports are 
available, volume expansion of the order of 40 mL/kg (the 
largest volume in FEAST) increases 48-hour mortality. 
Yet there is a growing body of evidence that a positive 
ﬂ  uid balance might contribute to signiﬁ  cant morbidity in 
patients with sepsis [15], acute respiratory distress 
syndrome [16], acute kidney injury [17], or major surgery 
[18]. It is, therefore, biologically and physiologically 
plausible that excessive ﬂ  uid administration is harmful 
but that, owing to the masking eﬀ  ects of other supportive 
interventions, such harm is not immediately recognized 
in a Western context. Th  us, mechanical ventilation, 
inotropes, vaso  pressors, and CRRT prevent increases in 
early mortality but at the price of delayed and un  recog-
nized increases in the risk of a more prolonged subse-
quent organ failure [16,17]. Relevant to such reﬂ  ections, 
the failure of short-term physiological gain to translate 
into medium- or long-term clinical beneﬁ  t has a long and 
sad history in critical care medicine [16,19,20].
FEAST will undoubtedly cause robust debate and 
anxiety as the totemic status of ﬂ  uids in sepsis becomes 
undermined. Th  is is a result that Sigmund Freud, the 
author of Totem and Taboo [21], would have anticipated. 
His and our answer is the n  eed to confront and more 
fully investigate. To question the role of ﬂ  uids in severe 
sepsis can no longer be considered taboo.
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